GlassScriptPhysician profile
Stephanie L Baker
NPI 1497215891
$3,830.26
in general payments reported to CMS, 2019-2025
30 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.97 · 2021: $14.63 · 2022: $299 · 2023: $1,415 · 2024: $1,691 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $418.94 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $390.23 | 2022-2025 | |
| Abbvie INC. | $369.32 | 2022-2025 | Ubrelvy, Qulipta |
| Novo Nordisk INC | $347.61 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $322.33 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $269.82 | 2022-2025 | |
| Glaxosmithkline, LLC. | $260.15 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $252.17 | 2022-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.30 | 2022-2024 | Jardiance, Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.46 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $133.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $129.44 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $83.68 | 2022-2023 | Belsomra, Verquvo, Steglatro |
| Xeris Pharmaceuticals, INC. | $79.07 | 2023-2025 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $63.16 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $60.70 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $45.68 | 2023-2024 | Veozah |
| Boston Scientific Corporation | $40.97 | 2022-2024 | |
| Eisai INC. | $37.43 | 2024-2025 | |
| Dexcom, INC. | $24.38 | 2024 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $23.88 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Tris Pharma INC | $23.15 | 2024 | Dyanavel Xr |
| Medtronic, INC. | $17.81 | 2025 | Inceptiv |
| Kestra Medical Technology Services, INC. | $17.00 | 2024 | Assure Wcd |
| Sunovion Pharmaceuticals INC. | $16.51 | 2022 | |
| Phadia US INC. | $16.26 | 2023 | Immunocap |
| Radius Health, INC. | $14.96 | 2024 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $14.58 | 2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2024 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $13.51 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.